By Tiffany Hu ( January 3, 2018, 4:43 PM EST) -- Amgen Inc. in a brief unsealed Tuesday urged a Delaware federal judge to dismiss a claim by Genentech Inc. that it had breached a "binding" representation that it would market its biosimilar of cancer drug Avastin at a certain date, arguing the biotechnology rival "mischaracterize[d]" Amgen's statement....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.